Draupnir Bio

Draupnir Bio is a spin out company, from Aarhus University, Denmark and the Max-Planck Society, Germany. Backed by a syndicate of leading European investors – Gilde Healthcare Partners, Inkef Capital, Novo Seeds and MP Healthcare Venture Management – Draupnir is based in Copenhagen, with research operations centered in Aarhus, Denmark.

We are establishing ourselves at the forefront of extracellular targeted protein degradation, building a risk-diversified preclinical pipeline of oral, small molecule protein degraders against targets that are validated and those that have been traditionally difficult to drug.